A Study of LY2886721 in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this phase I study in healthy participants will be to evaluate the safety and tolerability of LY2886721 single and multiple doses, to evaluate how the body handles the drug, and to evaluate the drug's effect on the body.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3867070 in Healthy Participants

NCT07021547

Healthy

RECRUITING PHASE1

A Study of LY3053102 in Healthy Participants

NCT01736241

Healthy Volunteers

COMPLETED PHASE1

A Study of LY3461767 in Healthy Participants

NCT04352114

Healthy

COMPLETED PHASE1

A Study of LY3848575 in Healthy Participants

NCT05727072

Healthy

COMPLETED PHASE1

A Study of LY3537031 in Healthy Participants

NCT04648865

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Single oral dose and/or once daily (QD) oral dosing for 14 consecutive days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally.

35 mg LY2886721

QD oral dosing for 14 consecutive days

Group Type EXPERIMENTAL

LY2886721

Intervention Type DRUG

Administered orally.

70 mg LY2886721

Single oral dose or single oral dose followed by QD oral dosing for 14 consecutive days

Group Type EXPERIMENTAL

LY2886721

Intervention Type DRUG

Administered orally.

140 mg LY2886721

Single oral dose

Group Type EXPERIMENTAL

LY2886721

Intervention Type DRUG

Administered orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY2886721

Administered orally.

Intervention Type DRUG

Placebo

Administered orally.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy men and non-childbearing potential women
* Body mass index (BMI) between 18.0 and 32.0 kilograms per square meter (kg/m\^2)
* Are reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures and research unit policies

Exclusion Criteria

* Taking over-the-counter or prescription medication with the exception of vitamins or minerals
* Smoke more than 10 cigarettes per day
* Drink more than 5 cups of caffeine containing beverages (for example, coffee, tea) per day

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes